U.S. markets closed
  • S&P 500

    3,811.15
    -18.19 (-0.48%)
     
  • Dow 30

    30,932.37
    -469.64 (-1.50%)
     
  • Nasdaq

    13,192.35
    +72.92 (+0.56%)
     
  • Russell 2000

    2,201.05
    +0.88 (+0.04%)
     
  • Crude Oil

    61.66
    -1.87 (-2.94%)
     
  • Gold

    1,733.00
    -42.40 (-2.39%)
     
  • Silver

    26.70
    -0.98 (-3.56%)
     
  • EUR/USD

    1.2088
    -0.0099 (-0.81%)
     
  • 10-Yr Bond

    1.4600
    -0.0580 (-3.82%)
     
  • GBP/USD

    1.3922
    -0.0091 (-0.65%)
     
  • USD/JPY

    106.5500
    +0.3200 (+0.30%)
     
  • BTC-USD

    46,130.21
    +56.27 (+0.12%)
     
  • CMC Crypto 200

    912.88
    -20.25 (-2.17%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    28,966.01
    -1,202.26 (-3.99%)
     

Fate Therapeutics Inc (FATE) President and CEO J Scott Wolchko Sold $2 million of Shares

GuruFocus.com
·1 min read

- By insider

President and CEO of Fate Therapeutics Inc (30-Year Financial, Insider Trades) J Scott Wolchko (insider trades) sold 20,000 shares of FATE on 02/18/2021 at an average price of $102.01 a share. The total sale was $2 million.


Fate Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. Fate Therapeutics Inc has a market cap of $10.18 billion; its shares were traded at around $110.180000 with and P/S ratio of 487.52. GuruFocus has detected 3 severe warning signs with Fate Therapeutics Inc. .

CEO Recent Trades:

  • President and CEO J Scott Wolchko sold 20,000 shares of FATE stock on 02/18/2021 at the average price of $102.01. The price of the stock has increased by 8.01% since.

  • President and CEO J Scott Wolchko sold 60,000 shares of FATE stock on 01/22/2021 at the average price of $100.67. The price of the stock has increased by 9.45% since.

For the complete insider trading history of FATE, click here

.This article first appeared on GuruFocus.